Condition: Advanced Cancers · Sponsor: CAS Lamvac Biotech Co., Ltd.
The purpose of this study is to evaluate the safety of Plasmodium immunotherapy and preliminarily evaluate the effectiveness of Plasmodium immunotherapy for advanced cancers.The treatment will last 3-6 months from the day of successful infection and will be terminated by antimalarial drugs.
This description comes directly from the study's public registry record.
Li Qin, M.D · 0086-18802043960 · njlf@cas-lamvac.com
Suyi Zhang, M.D · 0086-20-82258805 · zhang_suyi@cas-lamvac.com
Always discuss trial participation with your own doctor first.
| Guangzhou Fuda Tumor Hospital | Guangzhou, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03375983